Simcere Pharmaceutical Group (SCR) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts SCR Hot Sheet
Join SI Premium – FREE
Simcere Pharmaceutical Group (NYSE: SCR) reported Q1 EPS of $0.08, $0.02 worse than the analyst estimate of $0.10. Revenue for the quarter came in at $77.4 million versus the consensus estimate of $84.31 million.
For earnings history and earnings-related data on Simcere Pharmaceutical Group (SCR) click here.
For earnings history and earnings-related data on Simcere Pharmaceutical Group (SCR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Parsons Corporation (PSN) Tops Q3 EPS by 11c, Beats on Revenue; Offers FY26 Revenue Guidance
- NiSource (NI) Tops Q3 EPS by 5c ; Offers Guidance
- V.F. Corp. (VFC) Tops Q2 EPS by 17c, Beats on Revenue
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
